Show simple item record

dc.contributor.authorHayman, E.G.
dc.contributor.authorPatel, A.P.
dc.contributor.authorJames, R.F.
dc.date.accessioned2019-10-08T19:43:53Z
dc.date.available2019-10-08T19:43:53Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85020187412&doi=10.3390%2fmolecules22050724&partnerID=40&md5=6d6817a76d8cb4583136a3c7ec593f09
dc.identifier.urihttp://hdl.handle.net/10713/11127
dc.description.abstractPharmacologic efforts to improve outcomes following aneurysmal subarachnoid hemorrhage (aSAH) remain disappointing, likely owing to the complex nature of post-hemorrhage brain injury. Previous work suggests that heparin, due to the multimodal nature of its actions, reduces the incidence of clinical vasospasm and delayed cerebral ischemia that accompany the disease. This narrative review examines how heparin may mitigate the non-vasospastic pathological aspects of aSAH, particularly those related to neuroinflammation. Following a brief review of early brain injury in aSAH and heparin's general pharmacology, we discuss potential mechanistic roles of heparin therapy in treating post-aSAH inflammatory injury. These roles include reducing ischemia-reperfusion injury, preventing leukocyte extravasation, modulating phagocyte activation, countering oxidative stress, and correcting blood-brain barrier dysfunction. Following a discussion of evidence to support these mechanistic roles, we provide a brief discussion of potential complications of heparin usage in aSAH. Our review suggests that heparin's use in aSAH is not only safe, but effectively addresses a number of pathologies initiated by aSAH.en_US
dc.description.sponsorshipThis work was supported by grants to JMS from the National Institute of Neurological Disorders and Stroke (NS060801; NS061808) and the National Heart, Lung and Blood Institute (HL082517).en_US
dc.description.urihttps://doi.org/10.3390/molecules22050724en_US
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofMolecules
dc.subjectBrain injuryen_US
dc.subjectEdemaen_US
dc.subjectEnoxaparinen_US
dc.subjectHeparinen_US
dc.subjectInflammationen_US
dc.subjectSubarachnoid hemorrhageen_US
dc.titleHeparin and heparin-derivatives in post-subarachnoid hemorrhage brain injury: A multimodal therapy for a multimodal diseaseen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/molecules22050724
dc.identifier.pmid28468328


This item appears in the following Collection(s)

Show simple item record